Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > Cardiovascular > Flashcards

Cardiovascular Flashcards

1
Q

Stage I (SBP 140-159 & DBP 90-99) HTN: med used

A
  • Diuretics: thiazide-type
  • May consider angiotensin-converting enzyme (ACEI), angiotensin receptor blocker (ARB), calcium channel blocker (CCB), or combination
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Stage II (SBP greater than or equal to 160/ DBP greater than or equal to 100) HTN: meds used

A
  • Two-drug combination: thiazide-type & ACEI, ARB, BB, CCB
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Heart Failure Stage A: meds used

A

ACEI are drug of choice

ARBs are considered but more expensive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Heart Failure Stage B: Meds used

A

ACEI in all patients, ARBs for those who cannot tolerate ACEI

BB in most

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Heart Failure Stage C: Meds Used

A

ACEI and BBs (nonselective) in all patients

Diuretics, digoxin

Spironolactone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Heart Failure Stage D: Meds Used

A

Sacubitril/Valsartan (Entresto) in lieu of ACE or ARB

Inotrope: dobutamine

Ventricular assist device, transplantation, hospice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ACE Inhibitors: Pharmacodynamics

A

Inhibition of angiotensin-converting enzyme (ACE) activity results in decreased production o both angiotensin II and aldosterone
Can lower vascular resistance without decreasing CO or GFR
Does not produce reflex tachycardia
Strong evidence for CV & cerebrovascular risk reduction, HF, & slowing renal disease. Improves oxygenation to heart muscle, decreases inappropriate remodeling of heart muscle after MI or HF, reduces effects of diabetes on kidneys
Improves insulin sensitivity, does not affect glucose metabolism or raise serum lipid levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ACE Inhibitor: Clinical Uses

A

Younger caucasian patients:

  • Patients w/ angina: prevent formation of AT II & decreases pulmonary vascular resistance by decreasing retention of NA & water & reduces extracellular fluid & preload
  • Patients w/ diabetes: prevents or slows neuropathy
  • After MR or HF, for ventricular remodeling

Not as effective in African American patients- when combined with diuretic, race no longer an issue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ACE Inhibitors: ADRs

A

3-4x greater risk of angioedema in African Americans & Asians

Dry cough (bradykinin-mediated), hypotension, loss of taste, angioedema, blood dyscrasias, teratogenicity, hyperkalemia, acute renal failure, cholestatic jaundice, pancreatitis, rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

ACE Inhibitor: Monitoring and Patient Education

A

Monitoring:
- Possible orthostasis within 1 hour of admin. when starting & with each dosage change

Patient education:

  • Do not double dose if one is missed
  • Hypotension most common ADR
  • Cough common with older-generation agents
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Function of RAAS (Renin-Angiotensin-Aldosterone System)

A

Regulator of BP and determinant of target-organ damage

It controls fluid and electrolyte balance through coordinating effects on the heart, blood vessels, and kidneys

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Angiotensin II Receptor Blockers (ARBs): Pharmacodynamics

A

Prevent binding of AT II to receptors in kidney, brain, heart, and arterial walls
Inhibit the RAAS and cause fall in peripheral resistance
Evidence supports use in kidney disease until late stage and HF, but not all forms are renal protective like ACEI
No bradykinin-mediated cough like with ACEI
Considered alternatives for patients who cannot tolerate ACE or become resistant
Many combined with HCTZ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ARBs: ADRs, Monitoring, and Patient Education

A

ADRs:
- Similar to ACEIs but typically no problem with cough

Monitoring:
- Like ACEI, orthostasis with dose changes

Patient Education:

  • Do not double dose if one is missed
  • Hypotension most common ADR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Direct Renin Inhibitors (DRI)- Alsikiren (Tekturna): Pharmacodynamics

A

Works on the RAAS
Can be used for HTN, awaiting word on HF; not same MI indication as ACEI or ARB

Does not have the same renal protective properties as ACEI
For example, ACEI must stop when creatinine rises

Same issues in pregnancy, perhaps fewer issues with K+ and cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Neprilysin Inhibitors (New Drug Class)

A

Sacubitril/valsartan (Entresto) decreases hospitalizations & death in chronic HF
- Ejection fraction (EF) < 40%

Taken in place of ACE or ARB

Not given with BBs, such as carvedilol

Increases renal blood flow & improves diuresis

Require 36-hour washout between ACE/ARB/BB

Sometimes called “game changer medication”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Calcium Channel Blockers (CCBs): Pharmacodynamics

A

Functionally act as vasodilators, lowering calcium influx into smooth muscles

First choice for African Americans with HTN
- can be used as add-on medications for others

Two classes:

  • Type I - Non-dihydropyridines
  • Type II - Dihydropyridines
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

CCB Type I

A

Non-dihydropyridines

Affect conduction through the atrioventricular (AV) node and have negative chronotropic effects

  • Used in treating supraventricular tachycardia
  • Diltiazem (cardizem), verapamil (Calan)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

CCB Type II

A

Dihydropyridines

Do not affect conduction through the AV node
- Nifedipine (procardia), amlodipine (Norvasc), felodipine (Plendil)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

CCB: Metabolism, ADRs, Monitoring

A

Metabolized by the liver, CYP450 3A4

ADRs:
- very constipating and can cause dizziness, HA, edema, rash, and gingival hyperplasia

Monitoring:

  • Verapamil has strongest negative inotropic effect and should be avoided in patients with HF
  • CCB/ACE combination decreases peripheral edema by 50% vs high-dose CCB alone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

CCBs: Patient Education

A

Pregnancy Category C

Avoid NSAIDs, alcohol, being in a jacuzzi alone

GERD symptoms get worse because of decrease esophageal tone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Cardiac Glycosides: dose

A

Serum concentrations greater than 1 mg/mL increase mortality

- Initiate therapy at the lowest dose possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Cardiac Glycosides- Digoxin: pharmacodynamics

A

Highly selective inhibitor of adenosine triphosphatase (ATPase) system
- Inhibition of this pump results in sodium & calcium buildup inside the cell, which leads to increased contractility of heart muscle

New research shows it may increase mortality in women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Cardiac Glycosides- Digoxin: Use, Half-Life, Drug Interaction

A

Benefits are best in patients with severe HF, enlarged heart, & third heart sounds, & in patients who do not respond to ACEI & BBs

Well absorbed orally

Not extensively metabolized, excreted unchanged by kidneys

Half-life is 36-48 hours

  • In the absence of oral or IV loading, steady state is achieved in four half-lives or 1 week
  • Reduced clearance of digoxin with drug interaction- Quinidine, amiodarone, verapamil, diltiazem
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Cardiac Glycosides- Digoxin: ADRs

A

GI most common: anorexia, N/V, diarrhea
CNS: fatigue, disorientation, depressio, hallucinations, visual disturbances (yellow vision & green halos around lights)
Toxicity: atrial arrhythmias/tachycardia in children
Cardiac: bradycardia, PVCs, junctional & atrioventricular (AV) block arrhythmias, & bigeminy

Avoid using in patients with normal left ventricular systolic function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Cardiac Glycoside- Digoxin: Monitoring and Patient Education

A

Monitoring:

  • Diagnosis of toxicity is based on both clinical & lab data
  • Toxicity commonly occurs with serum levels greater than 2 mg/mL
  • Monitor Potassium levels (it can cause high potassium)

Patient Education:

  • Take at same time each day
  • Do not double dose
  • Monitor for signs of toxicity
  • Take pulse, hold for HR less than 60 or greater than 100 bpm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Absolute Refractory Period

A

Regardless of the strength of a stimulus, the cell cannot be depolarized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Relative Refractory Period

A

Stronger-than-normal stimulus can induce depolarization

28
Q

Refractoriness

A

State of the cardiac cell which determines depolarization

Damaged heart cells may maintain a constant rate of refractoriness or may not be refractory at all

29
Q

Class IA: Sodium Channel Blockers

A

Lengthen the duration of action potential (slows HR)

30
Q

Class IB: Sodium Channel Blockers

A

Shorten the duration of action potential

31
Q

Class IC: Sodium Channel Blockers

A

Minimally increase action potential

32
Q

Class II: Beta blockers

A

Reduce adrenergic activity in the heart

Sotalol: considered a class II and III drug

33
Q

Class III: Potassium Channel Blockers

A

Prolong effective refractory period and reduce speed of conduction

Amiodarone

34
Q

Class IV: Calcium Channel Blockers

A

Block influx of calcium, reduce contractility (negative inotropism), decrease SA and AV code conduction

Significantly reduce afterload but little effect on preload

Verapail, diltiazem, bepridil

35
Q

Beta Adrenergic Blockers: Pharmacodynamics

A

Various types include nonspecific beta antagonists, selective beta antagonists, and those with or without intrinsic sympathomimetic activity (ISA)

  • In post-MI patients, cardioselective agents without ISA are preferred
  • Some are used as antiarrhythmics
  • Drugs with ISA may help avoid a decrease in cardiac output (CO) and HR. May be preferred for patients who experience bradycardia with other BBs

More effective in African Americans & older patients
BBs may not be abruptly withdrawn, because it will increase beta receptor sensitivity
No longer first-line HTN drug choice

36
Q

Amiodarone: Pharmacodynamics/kinetics

A

Class III antiarrhythmic

Onset of action: oral- 2 days to 3 weeks
Duration of action: 7 to 50 days
Excreted in feces, 1% urine
Dosing: watch out for use in grapefruit juice
- Ventricular arrhythmias: 800-1600 mg BID for 1-3 weeks, then decreased to 300-400 mg BID, maintenance 400 mg/day

37
Q

Amiodarone: ADRs, drug interaction

A

ADRs:
- Thyroid, neurological, blue skin discoloration, bradycardia, lung damage not evident until advance

Many drug interactions

38
Q

Monitoring and Patient Education for all Antiarrhythmics

A

Monitoring:

  • Potassium, blood urea nitrogen (BUN), creatinine, therapeutic drug levels
  • ECG

Patient Education:

  • Take exactly as prescribed; do not double dose
  • Be aware of food-drug interactions
  • Monitor HR for regularity of rate and rhythm
  • Monitor BP at home
39
Q

Nitrates: ADRs

A

HA, orthostatic hypotension w/ potential for syncope & tachycardia (direct extensions of therapeutic vasodilation)
HA may be severe & persists in up to 50% of patients
Hypotension may lead to decrease in diastolic filling pressure & tachycardia may lead to decrease in diastolic filling time, which may lead to myocardial ischemia, arrhythmias, and rebound HTN
Contact dermatitis can occur with transdermal patches

40
Q

Nitrates: Drug Interactions

A

Concurrent use with vasodilators or with erectile dysfunction drugs sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) contraindicated

Additive hypotension with antihypertensives, alcohol, BBs, CCBs

41
Q

Nitroglycerin: Use, & Dosing

A

Clinical Use:

  • Acute angina attack (use NTG)
  • —-sublingual NTG, a short-acting form, 0.4-0.6 mg every 5 minutes for up to 3 doses
  • Stable or Predictable angina (use isosorbide):
  • —-Isosorbide dinitrate: 10-40 mg orally 2-3 times daily; sustained-release form 40-80 mg daily
  • —-Isosorbide mononitrate: dosing is 20 mg BID
  • —-Eccentric scheduling to avoid development of tolerance
42
Q

Nitroglycerin: Patient Education

A

Take the drug exactly as prescribed

  • Eccentric dosing schedule is separated by 7 hours because of need to have nitrate-free period
  • Take at 7 to 8 am and 2 to 3 pm rather than “usual” twice daily regimen
  • A nitrate-free interval of 10-12 hours is needed

If anginal symptoms occur at night, have a daytime nitrate-free interval

Storage of NTG

  • Adhere to the expiration date on bottle, usually 6 months
  • Do not open bottle frequently or keep bottles of tabs nest to body (e.g., in a shirt pocket)
43
Q

Peripheral Vasodilators: Pharmacodynamics

A

Hydralazine and Minoxidil

There are NOT used as first line HTN

Minoxidil is more potent vasodilator and has more dramatic compensator response

These drugs act by direct relaxation and dilation of arteriolar smooth muscle, decreasing peripheral vascular resistance

44
Q

Peripheral Vasodilators: ADRs, Drug Interactions, & Dosing

A

ADRs: related to compensatory responses in the sympathetic nervous system & RAAS- tachycardia, increased cardiac contractility & output, sodium & water retention, HA

Drug interactions: additive effects with other antihypertensive; NSAIDs may decrease their effect

Dosing:
- HTN: hydralazine 25-100 mg QID; max dose 200 mg/day

45
Q

Peripheral Vasodilators: Monitoring & Recommendations

A

Most patients should return for follow-up & adjustment of meds at monthly intervals or until the BP goal is reached.

Serum potassium & creatinine should be monitored at least one to two times per year

After BP is at goal & stable, follow-up visits can usually be at 3-6 month intervals

Co-morbidities such as HF, associated diseases such as diabetes, and the need for lab tests influence the frequency of visits

Other CV risk factors should be monitored & treated to their respective goals, and tobacco avoidance must be promoted vigorously

Low-dose aspirin therapy should be considered only when BP is controlled because of increased risk of hemorrhagic stroke when BP high

46
Q

Pathophysiology of Hyperlipidemia

A

Atherosclerosis is a major cause of CAD
Lipoproteins: all contain triglycerides (TGs), phospholipids, & cholesterol
- Low density (LDL), high density (HDL), very low density (VLDL), TGs

Exogenous pathway: involves absorption of lipids via intestine
Endogenous pathway: lipids originate from liver

47
Q

Statins- HMG CoA Reductase Inhibitors: Pharmacodynamics

A
  • Block synthesis of cholesterol in liver by competitively inhibiting HMG CoA reductase activity
  • Decreases levels of LDL by 25-65%
  • Modest decreases in TGs (10-40%) and very modest increases in HDL (5%-17%) may occur
  • Pregnancy: old category X; fully contraindicated
48
Q

Statins: CYP3A Interactions

A
  • All statins (except fluvastatin & rosuvastatin) are metabolized at least in part by CYP3A
  • CYP3A inhibitors may increase statin concentrations
  • –Verapamil, diltiazem, azole antifungals, erythromycin, fluoxetine, nefazodone, protease inhibitors
  • CYP3A inducers may decrease statin concentrations
  • –Rifampin, phenytoin, phenobarbital
  • Statins may also interact with other CYP channel substrates; for example cyclosporine
49
Q

Statin ADRs

A

Common: HA, myalgia, fatigue, GI intolerance, flu-like symptoms
Myopathy: occurs in 0.2-0.4% of patients, some agents more likely
- Reduced by using lowest effective dose; cautiously combining statins with fibrates; avoiding drug interactions
Increase in liver enzymes NOT ENOUGH to warrant frequent lab tests
- Active liver disease is a contraindication; occurs in 0.5-2.5% of cases & is dose-dependent; serious liver problems are rare; manage by reducing dose or stopping until levels return to normal

50
Q

Statins- HMG CoA Reductase Inhibitors: Dosing

A

Start with lower dose & increase, as needed, according to LDL response; absolute levels of LDL not as closely monitored now

Rosuvastatin most potent: 5-20 mg daily
Atorvastatin next most potent (Best ADR profile): 10 mg/day initially, increase no fewer than 2-4 weeks
Simvastatin: 20-40 mg/day
Lovastatin: (IR) 20 mg/day, (ER) 40-60 mg
Provastatin: 40 mg/day; pediatric dosing for children 8-13 years: 20 mg/day

Doses often are given traditionally in evening/bedtime
May need to decrease dose occasionally: when adding potentially interacting drug; profound drop in LDL

51
Q

Statin: Monitoring and Patient Education

A

Monitoring:

  • Lipid levels in 4-6 weeks then ever 3-4 months until controlled
  • LDL levels guide dose increases
  • LFTs before starting therapy & 3-6 months later only if suspected issues or underlying hepatic issues

Patient Education:
- Lifestyle changes (diet, exercise)

52
Q

Fibrates- Fibric Acid Derivatives: Mechanism of Action (MOA)

A

Inhibition of cholesterol synthesis
Decreased triglyceride synthesis
Inhibition of lipolysis in adipose tissue
Decreased production of VLDL/increased clearance
Increased plasma & hepatic lipoprotein lipase (LPL) activity

Effects on lipids

  • Decreases total cholesterol (TC), LDL, TGs
  • Increases HDL
53
Q

Fibrates- Fibric Acid Derivatives: Pharmacodynamics

A

Effective TG-lowering drugs that modestly lower LDL & raise HDL for only some patients
Work for patients with very high TG levels, such as patients with type 2 diabetes & with familial dysbetalipoproteinemia
These drugs do NOT produce substantial reduction in LDL, so are not appropriate as initial or monotherapy

54
Q

Fibrates: Dosing, ADRs, Drug Interactions

A

Dosing:

  • Gemfibrozil: 600 mg BID
  • Micronized Fenofibrate: 67 mg QID, max 201 mg
  • Clofibrate: 2 g daily in divided doses

ADRs:
- nausea, diarrhea, cholelithiasis, phototoxicity

Drug Interactions:

  • Increased risk of hepatotoxicity and/or myalgias with concurrent statins and/or niacin
  • Protein-binding displacement (e.g., warfarin)
55
Q

Fibrates: Monitoring & Patient Education

A

Monitoring:

  • Lipid levels in 4-6 weeks, then every 3-4 months until controlled
  • LDL levels will drop when triglycerides drop
  • LFTs before starting and PRN

Patient Education:

  • Take as directed
  • ADRs: constipation & flatulence
  • Lifestyle changes (diet & exercise)
56
Q

Bile Acid Sequestrants: Pharmacodynamics

A

By promoting an increase in bile acid excretion, they enhance conversion of cholesterol to bile acids by the liver & increase uptake of LDL

Bind with cholesterol in the intestine and are NOT metabolized by liver

Excreted in bound form in feces

May use with patient with active liver disease

Lower TC, LDL, and TG, and increases HDL, in theory

57
Q

Bile Acid Sequestrants: Use

A

Strong record of efficacy & safety

Most useful for patients with moderately elevated LDL levels & low coronary heart disease (CHD) risk profile

Patients who are not able to reduce their LDLs with lifestyle modifications

Can be used together with fibrates

58
Q

Bile Acid Sequestrants: ADRS, Dose, Drug Interactions

A

ADRs:

  • GI- constipation, bloating, abdominal pain, unpleasant taste & texture; HA
  • Reduced folate levels with long-term use

Dosing:
- Initial dose: one packet mixed with juice; never swallow in dry form

Drug Interactions:
- Interfere with absorption of other medications

59
Q

Bile Acid Sequestrants: Monitoring and Patient Education

A

Monitoring:

  • Lipid levels
  • Bowel issues

Patient Education:

  • Taken with meals mixed with 4-6 oz of fluid
  • Other drug absorption impaired if taken at the same time
  • ADRs: constipation, may need stool softeners
  • Lifestyle changes (diet & exercise)
60
Q

Niacin

A
  • No longer approved by FDA for use in lipid management
  • Previous touted effects on lipids (lower TC, LDL, TG, & elevate HDL)
  • Increased risk CV events if taken at doses to change lipids. Adverse events STRONGER than any benefit
  • OTC doses are not sufficient to lower LDL (flush-free have no CV effect)
  • Does not raise enough of the HDL to counter the increase in CV events without evidence of benefit
  • No evidence (yet) that actually increasing HDL is helpful
61
Q

Ezetimibe (Zetia)

A
  • Selectively inhibits intestinal absorption of cholesterol & related phytosterols
  • Has been shown to reduce TC, LDL, & TG while increasing HDL-C
  • No good outcome data yet, but most effective in combination with statin
  • Dosing: 10 mg/day
  • Pregnancy category C; not for children younger than 10 years of age
62
Q

Thiazide Diuretics

A
  • HCTZ, chlorthalidone, indapamide, metolozone
  • High dose therapy (HCTZ greater than 50) has increased risk of hypokalemia, increase in uric acid levels, and serious CV outcomes; use in combination vs. pushing high doses
  • Watch with patients with hyperlipidemia
63
Q

Loop Diuretics

A

Potential for cross-sensitivity with sulfa

Furosemide, bumetanide, torsemide

64
Q

Potassium Sparing Diuretic

A

Often used in combination with thiazide to reverse low potassium effect

Triamterene, Spironlactone, Eplerenone (Inspra)

Eplerenone (Inspra)- next generation aldosterone agent
- Potassium sparing, selective aldosterone blocker

65
Q

Diuretics: ADRs

A

Hypotension, decreased GFR, hypokalemia/hyperkalemia, electrolyte abnormalities, metabolic alkalosis, hyponatremia

66
Q

Diuretics: Metabolism and Cost

A

Major CYP3A4 substrate

  • Decreased effects with NSAIDs
  • Drug effects increase with grapefruit juice, azoles, CCBs
  • Increases effects of ACEI, ARB, BB, potassium replacement

Cost:
- Approximately $110 to $125/month without superior outcomes

67
Q

Diuretics: Monitoring & Patient Education

A

Monitoring:

  • BP, HR, edema, weight gain, dyspnea, cough, urine output
  • Prior to initiating therapy- BUN, creatinine, electrolytes (sodium, potassium, calcium, magnesium), uric acid, & glucose levels
  • Ongoing monitoring of electrolytes

Patient Education:

  • Take as directed early in day if there are urination issues
  • Do not skip or double dose
  • Monitor weight
  • Must drink fluids!!

Pharmacology (25 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions